New Phase 3 trials registered, week of October 12, 2026: 10 industry trials
Industry sponsors registered 10 Phase 3 trials on ClinicalTrials.gov so far in the week of October 12 to 18, 2026. They plan to enroll 22,480 participants in all; the largest, GlaxoSmithKline's RZV vaccine trial, plans to enroll 16,390.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, October 18, 2026.
The trials
- GlaxoSmithKline registers Phase 3a study of recombinant zoster vaccine for cardiovascular events. Sponsor: GlaxoSmithKline. Condition: Cardiovascular Disease. Intervention: RZV vaccine. Phase: Phase 3. Planned enrollment: 16,390. Planned primary completion: November 2032. First posted October 13, 2026. Record: NCT07872046.
- Merck registers Phase 3 trial of ensifentrine for COPD exacerbation prevention. Sponsor: Merck Sharp & Dohme LLC. Condition: Pulmonary Disease, Chronic Obstructive. Interventions: Ensifentrine, Standard of Care (SOC). Phase: Phase 3. Planned enrollment: 2,136. Planned primary completion: April 2029. First posted October 15, 2026. Record: NCT07874815 (ENHANCE-3).
- Hinova registers Phase 3 trial of Deutenzalutamide in high-risk BCR prostate cancer. Sponsor: Hinova Pharmaceuticals Inc. Conditions: High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules. Intervention: Deutenzalutamide Soft Capsules + ADT. Phase: Phase 3. Planned enrollment: 1,044. Planned primary completion: December 2029. First posted October 15, 2026. Record: NCT07875881.
- Il-Yang Pharm. Co. registers Phase 3 trial of UROCOM-R1 plus UROCOM-R2. Sponsor: Il-Yang Pharm. Co., Ltd. Condition: Benign Prostatic Hyperplasia. Interventions: Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule. Phase: Phase 3. Planned enrollment: 660. Planned primary completion: August 2027. First posted October 13, 2026. Record: NCT07870759.
- Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis. Sponsor: Takeda. Condition: Psoriatic Arthritis. Intervention: Zasocitinib. Phase: Phase 3. Planned enrollment: 644. Planned primary completion: April 2030. First posted October 13, 2026. Record: NCT07871721.
- Pfizer registers Phase 3 trial of PF-08653944 in Chinese adults with overweight or obesity. Sponsor: Pfizer. Conditions: Obesity, Overweight. Intervention: Berobenatide. Phase: Phase 3. Planned enrollment: 432. Planned primary completion: June 2028. First posted October 15, 2026. Record: NCT07874633.
- Onconic registers Phase 3 trial of JP-1366-based triple therapy for H. Pylori. Sponsor: Onconic Therapeutics Inc. Condition: H. Pylori Eradication Therapy. Phase: Phase 3. Planned enrollment: 414. Planned primary completion: September 2028. First posted October 15, 2026. Record: NCT07875933.
- Huons Biopharma registers Phase 3 trial of HU-045 in glabellar lines. Sponsor: Huons Biopharma. Condition: Glabellar Lines. Interventions: HU-045, Xeomin®. Phase: Phase 3. Planned enrollment: 390. Planned primary completion: May 2027. First posted October 13, 2026. Record: NCT07870694.
- Almirall registers Phase 3b trial of lebrikizumab in face and neck atopic dermatitis. Sponsor: Almirall, S.A. Condition: Atopic Dermatitis. Intervention: Lebrikizumab. Phase: Phase 3. Planned enrollment: 230. Planned primary completion: February 2028. First posted October 14, 2026. Record: NCT07873801 (ADface).
- AstraZeneca registers Phase 3 trial of durvalumab and FLOT in Chinese gastric cancer patients. Sponsor: AstraZeneca. Conditions: Gastric, Esophagogastric Junction. Interventions: FLOT Chemotherapy, Durvalumab. Phase: Phase 3. Planned enrollment: 140. Planned primary completion: November 2029. First posted October 16, 2026. Record: NCT07877818.
By the numbers
- Trials: 10, from 10 lead sponsors.
- Planned enrollment: 22,480 in all across 10 trials; median 538 per trial.
- Largest: GlaxoSmithKline's RZV vaccine trial, 16,390. Smallest: AstraZeneca's FLOT Chemotherapy trial, 140.
- Phases as registered: 10 Phase 3.
- Planned primary completion: from May 2027 to November 2032.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.